Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access Poster presentation

TRAP1 and SORCIN cooperate in a survival pathway responsible for inducing drug-resistance in human colorectal carcinoma (CRC)

Matteo Landriscina1*, Francesca Maddalena1, Gabriella Laudiero2, Maria R Amoroso2, Annamaria Piscazzi1, Valentina Lombardi1, Alberto Fersini3 and Franca Esposito2

Author Affiliations

1 Clinical Oncology Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy

2 Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy

3 General Surgery Unit, Department of Surgical Sciences, University of Foggia, Foggia, Italy

For all author emails, please log on.

BMC Proceedings 2010, 4(Suppl 2):P37  doi:10.1186/1753-6561-4-S2-P37


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/4/S2/P37


Published:24 September 2010

© 2010 Landriscina et al; licensee BioMed Central Ltd.

Poster presentation

TRAP1, a mitochondrial chaperone with antiapoptotic functions, is involved in drug-resistance in human CRC. TRAP1 is a component of the HSP90 mitochondrial survival pathway, which antagonizes the proapoptotic activity of cyclophilin D. Interestingly, novel agents are able to disassemble this pathway and are under clinical evaluation.

GST-pulldown experiments and mass spectrometry assays led us to the identification of several TRAP1 ligands and, among others, Sorcin, a Ca2+-binding protein involved in the MDR phenotype of human tumors. We functionally characterized the cooperation between TRAP1 and Sorcin in favoring survival of CRC cells and investigated the expression levels of the two proteins in human CRCs.

We demonstrated the mitochondrial localization of a 18kDa isoform of Sorcin that specifically interacts with TRAP1 in human CRC cells. The overexpression or down-regulation of Sorcin and/or TRAP1 allowed us to demonstrate a reciprocal regulation between the two proteins and to show that their interaction is required for Sorcin mitochondrial localization and TRAP1 protein stability. Furthermore, the upregulation of either TRAP1 and/or Sorcin induced resistance to 5-fluoruracil (FU), irinotecan (IRI) and oxaliplatin (l-OHP) in CRC cells. Of note, the knock-down of TRAP1 and/or Sorcin expression by siRNAs as well as the pharmacological inhibition of TRAP1 ATPase re-established a phenotype sensitive to FU, IRI and l-OHP. Consistently with these in vitro observations, gene expression analysis showed that TRAP1 and Sorcin are up-regulated, respectively, in 28/41 and 18/41 CRCs and a significant correlation between the expression of TRAP1 and the p22 isoform of Sorcin was observed (Sperman rank test p = 0.003; Kendal Tau test p = 0.003). Finally, the two proteins are also co-upregulated in CRC cells resistant to FU, IRI and l-OHP.

Sorcin and TRAP1 are functionally linked in a survival network responsible for resistance to chemotherapy in CRCs. Thus, TRAP1 pathway deserves to be further evaluated as molecular target to overcome drug resistance in human CRC.